Report overview
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
This report aims to provide a comprehensive presentation of the global market for Drugs for Neuromyelitis Optica, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Neuromyelitis Optica. This report contains market size and forecasts of Drugs for Neuromyelitis Optica in global, including the following market information:
Global Drugs for Neuromyelitis Optica Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Drugs for Neuromyelitis Optica Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Drugs for Neuromyelitis Optica companies in 2022 (%)
The global Drugs for Neuromyelitis Optica market was valued at US$ 48 million in 2022 and is projected to reach US$ 61 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
We surveyed the Drugs for Neuromyelitis Optica manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Neuromyelitis Optica Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, by Type, 2022 (%)
Glucocorticoids
Immunotherapies
Other
Global Drugs for Neuromyelitis Optica Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, by Application, 2022 (%)
Acute Attack
Remission Prophylactic Treatment
Global Drugs for Neuromyelitis Optica Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Drugs for Neuromyelitis Optica Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Neuromyelitis Optica revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Neuromyelitis Optica revenues share in global market, 2022 (%)
Key companies Drugs for Neuromyelitis Optica sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Neuromyelitis Optica sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Neuromyelitis Optica, market overview.
Chapter 2: Global Drugs for Neuromyelitis Optica market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Neuromyelitis Optica manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Neuromyelitis Optica in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Neuromyelitis Optica capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
